Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment

Re, M.D. (Marzia Del), Addeo, A. (Alfredo), Passaro, A. (Antonio), Petrini, I. (Iacopo), R.H.N. van Schaik (Ron) and R. Danesi (Romano)

2019-12-01

Pharmacogenomics , Volume 20 - Issue 18 p. 1255- 1257

Additional Metadata
Keywords	circulating biomarkers, EGFR, immunotherapy, NSCLC, predictive biomarkers
Persistent URL	doi.org/10.2217/pgs-2019-0150, hdl.handle.net/1765/122727
Journal	Pharmacogenomics
Organisation	Department of Clinical Chemistry
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Re, M.D. (Marzia Del), Addeo, A. (Alfredo), Passaro, A. (Antonio), Petrini, I. (Iacopo), van Schaik, R., & Danesi, R. (2019). Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. Pharmacogenomics, 20(18), 1255–1257. doi:10.2217/pgs-2019-0150

Publication